POXEL — Poxel SA Share News
0.000.00%
Last trade - 00:00- €9.32m
- €68.25m
- €6.64m
Brief: Poxel: Phase 2 For PXL065 In Nash Achieved Primary Efficacy Endpoint For Liver Fat Content Reduction For All Doses
Europe Research Roundup: A.P. Moller-Maersk, Home24 SE, Reckitt
Brief: Poxel: FDA Grants Orphan Drug Designation To PXL770
Brief: Poxel H1 Operating Loss Widens To EUR 12.2 Mln
Brief: Poxel Announces Positive Histology Results In PXL065 Trial
Brief: Poxel Announces Positive Results From Phase 2 NASH Trial For PXL065
Advisory: Alerts on Poxel dividend, outlook withdrawn
Brief: Poxel Publishes Two Preclinical Articles On X-Linked Adrenoleukodystrophy
Brief: Poxel Announces New Solid Form Patent For PXL065
French and Benelux stocks-Factors to watch
Brief: Poxel's PXL065, PXL770 Granted Orphan Drug Designation By FDA
Brief: Poxel Q1 Cash Flow At EUR 24.0 Mln
Brief: Poxel Says PXL770 Awarded FDA Fast Track Designation For X-Linked Adrenoleukodystrophy
French and Benelux stocks-Factors to watch
Brief: Poxel FY Net Loss Narrows To 23.8 Million Euros
Brief: Poxel Announces PXL065 Granted FDA Fast Track Designation For X-Linked Adrenoleukodystrophy
Brief: Poxel FY Revenue Rises To EUR 13.4 Million
UCB remains Jefferies' biotech top pick, hikes Zealand Pharma to 'buy'
Brief: Poxel Announces Formation Of Scientific Advisory Board For Rare Metabolic Diseases